ScinoPharm Taiwan, Ltd.

1789

TW0001789006

Pharmaceuticals

End-of-day quote Taiwan S.E. Other stock markets 23:00:00 06/06/2024 BST			5-day change	1st Jan Change
28.85 ^TWD	+1.23%		+3.59%	+9.28%

05-28	Scinopharm Taiwan, Ltd. Announces Tenure Expiration of the Company's Compensation Committee	CI
05-28	Scinopharm Taiwan, Ltd. Announces Audit Committee Changes	CI

ScinoPharm Taiwan, Ltd. Appoints Kao-Huei Cheng as General Chief Strategy Officer

December 18, 2015 at 04:36 pm

The Board of ScinoPharm Taiwan, Ltd. announced that Kao-Huei Cheng, Chairman of the company, Chairman of Tainan Spinning Co., Ltd. has been appointed as general Chief Strategy Officer. The effective date is December 18, 2015.

Latest news about ScinoPharm Taiwan, Ltd.

Scinopharm Taiwan, Ltd. Announces Tenure Expiration of the Company's Compensation Committee	05-28	CI
Scinopharm Taiwan, Ltd. Announces Audit Committee Changes	05-28	CI
Scinopharm Taiwan, Ltd. Elects Lai-Shou Su as Independent Director	05-28	CI
Scinopharm Taiwan, Ltd. Approves Cash Dividend for 2023	05-28	CI
ScinoPharm Taiwan, Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-10	CI
ScinoPharm Taiwan, Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	02-26	CI
ScinoPharm Taiwan, Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-07	CI
ScinoPharm Taiwan, Ltd. Announces Executive Changes	11-03	CI
ScinoPharm Taiwan, Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	07/08/23	CI
ScinoPharm Taiwan, Ltd. Announces Compensation Committee Appointments	29/05/23	CI
ScinoPharm Taiwan, Ltd. Announces Independent Director Appointments	29/05/23	CI
ScinoPharm Taiwan, Ltd. Approves Cash Dividend for 2022, Payable on July 28, 2023	29/05/23	CI
ScinoPharm Taiwan, Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	11/05/23	CI
ScinoPharm Taiwan, Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	01/03/23	CI
ScinoPharm Taiwan, Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	08/11/22	CI
ScinoPharm Taiwan, Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	05/08/22	CI
Scinopharm Taiwan, Ltd Approves Cash Dividend, Payable August 2, 2022	30/05/22	CI
ScinoPharm Taiwan, Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022	06/05/22	CI
ScinoPharm Taiwan, Ltd Announces Executive Changes	06/05/22	CI
ScinoPharm Taiwan, Ltd. Reports Earnings Results for the Full Year Ended December 31, 2021	25/02/22	CI
ScinoPharm Taiwan, Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	09/11/21	CI
Scinopharm Taiwan, Ltd. Reports Earnings Results for the Second Quarter Ended June 30, 2021	10/08/21	CI
ScinoPharm Taiwan, Ltd. Announces Cash Dividend, Payable on September 23, 2021	10/08/21	CI
Scinopharm Taiwan, Ltd. Approves to Distribute Cash Dividend	21/07/21	CI
ScinoPharm Taiwan, Ltd. Appoints Chih-Hui Lin as Corporate Governance Officer	11/05/21	CI

Chart ScinoPharm Taiwan, Ltd.

Duration

Period

More charts

Company Profile

ScinoPharm Taiwan Ltd is a Taiwan-based company mainly engaged in the research, development, manufacture and sale of active pharmaceutical ingredients. The main products include active pharmaceutical ingredients, protein drugs, oligonucleotides, peptides, injection preparations, new small molecule drugs and other chemical raw materials. The Company is also engaged in the provision of consulting and biotechnology services for related products, the international trading of products, as well as the provision of customized full-process services such as chemical molecular component synthesis, process development and commercial mass production. The Company operates within the domestic market and to overseas markets, including the Americas, Europe, Australia and Asia.

Sector

Pharmaceuticals

Calendar

06/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

28.85 TWD

Average target price

26 TWD

Spread / Average Target

-9.88%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
SCINOPHARM TAIWAN, LTD.	+9.28%	703M
ELI LILLY AND COMPANY	+45.82%	765B
NOVO NORDISK A/S	+40.95%	632B
JOHNSON & JOHNSON	-6.16%	354B
MERCK & CO., INC.	+19.86%	331B
ABBVIE INC.	+9.32%	299B
ASTRAZENECA PLC	+18.45%	248B
NOVARTIS AG	+11.88%	216B
ROCHE HOLDING AG	-0.78%	219B
AMGEN INC.	+5.90%	164B

Other Pharmaceuticals